Danish drugmaker Novo Nordisk warned Thursday that there might be continued provide constraints for Wegovy within the U.S. because it struggles to fulfill demand and that some sufferers will proceed to have hassle filling their prescriptions.
Whereas the capability for Wegovy is steadily growing, the provision of the decrease dose strengths will “stay restricted to safeguard continuity of care,” the drugmaker stated in its earnings report.
A spokesperson for Novo Nordisk instructed FOX Enterprise that it is particularly “limiting portions of 0.25 mg, 0.5 mg, and 1 mg dose strengths to wholesalers for distribution to retail pharmacies” to help continuity of look after present sufferers.
NOVO NORDISK WEIGHT LOSS DRUG WEGOVY CUTS HEART DISEASE RISK BY 20%, TRIAL SHOWS
Though it is producing and transport all dose strengths, the corporate stated “demand continues to outpace our growing manufacturing” and that provide disruptions might be ongoing.
The corporate is presently serving lots of of 1000’s of sufferers on Wegovy within the U.S.
The corporate instructed analysts Thursday that there was larger than anticipated quantity progress lately for its GLP-1-based merchandise comparable to Ozempic and Wegovy, that are the identical treatment – semaglutide. The corporate stated it expects “continued quantity progress” nevertheless it additionally admitted that it’s coping with “capability limitations at some manufacturing websites.”
WEGOVY, OZEMPIC: THE BARRIERS TO ACCESSING THESE WEIGHT LOSS DRUGS
The medicine went viral on social media final yr as TikTok customers and high-profile figures like Elon Musk touted their results as a weight reduction remedy. Docs feared that an inflow of individuals had been looking for the medicine as a “fast repair” for weight reduction, creating much less provide and doubtlessly hurting sufferers – particularly these with diabetes – who wanted the treatment.
Ozempic was accredited by federal well being officers in 2017 and marketed for medical use within the remedy of Kind 2 diabetes “with weight reduction as a secondary impact of the drug’s results and mechanism of motion.”
GET FOX BUSINESS ON THE GO BY CLICKING HERE
Wegovy was accredited 4 years later particularly for continual weight administration in adults who’re overweight or chubby and have at the least one weight-related situation comparable to hypertension, Kind 2 diabetes or excessive ldl cholesterol, in keeping with the Meals and Drug Administration.
Novo Nordisk has stated neither drug is “supposed for use as a life-style treatment.”